Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Símbolo desconocido
Fecha:
Ordernar por:
FechaHoraFuenteTítuloSímboloCompañía
01/06/202408:00Business WireAnkyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
01/06/202408:00Business WireSally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
01/06/202408:00PR Newswire (Canada)Statement by Minister Khera on Italian Heritage Month
01/06/202408:00PR Newswire (US)Vincent Todd Announces the Introduction of Todd Agriscience
01/06/202408:00PR Newswire (US)Beverly Hills MD Celebrates Its 10th Anniversary
01/06/202408:00PR Newswire (Canada)Déclaration de la ministre Khera à l'occasion du Mois du patrimoine italien
01/06/202408:00PR Newswire (US)American Cancer Society and American Society of Clinical Oncology Unite to Create One of the Largest and Most Comprehensive Online Sources of Credible Cancer Information
01/06/202408:00PR Newswire (Canada)Déclaration du premier ministre à l'occasion du Mois national de l'histoire autochtone
01/06/202408:00PR Newswire (Canada)Déclaration de la ministre Khera à l'occasion du Mois du patrimoine portugais
01/06/202408:00PR Newswire (Canada)Statement by the Prime Minister on National Indigenous History Month
01/06/202408:00PR Newswire (Canada)Déclaration de la ministre Khera à l'occasion du Mois du patrimoine philippin
01/06/202408:00PR Newswire (Canada)Statement by Minister Khera on Filipino Heritage Month
01/06/202408:00PR Newswire (Canada)Statement by Minister Khera on Portuguese Heritage Month
01/06/202408:00GlobeNewswire Inc.ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy SystemNASDAQ:CLPTClearPoint Neuro Inc
01/06/202408:00GlobeNewswire Inc.Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid TumorsNASDAQ:HOWLWerewolf Therapeutics Inc
01/06/202408:00CointelegraphMotoGP’s Gresini racing goes crypto with new fan sponsorship programCOIN:BTCUSDBitcoin
01/06/202407:58Alliance NewsAlliance NewsDIRECTOR DEALINGS: Coca-Cola HBC, M&S and Elementis execs sell sharesLSE:MKSMarks And Spencer Group Plc
01/06/202407:30PR Newswire (Canada)Message from the Governor General on National Indigenous History Month
01/06/202407:30PR Newswire (US)Xtalks Announces its Life Science Webinar Calendar for June 2024
01/06/202407:30PR Newswire (Canada)Message de la gouverneure générale à l'occasion du Mois national de l'histoire autochtone
01/06/202407:21Cointelegraph3 signs that Ethereum price will finally break $4K in JuneCOIN:ETHUSDEthereum
01/06/202407:15GlobeNewswire Inc.Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202407:10Business WireNuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual MeetingNYSE:NUVBPanacea Acquisition Corp
01/06/202407:05GlobeNewswire Inc.Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202407:05PR Newswire (US)Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024NASDAQ:JAZZJazz Pharmaceuticals PLC
01/06/202407:01Alliance NewsAlliance NewsEXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood TechLSE:TGRTirupati Graphite Plc
01/06/202407:00NEWSBTC$2.5 Billion In Bitcoin Flows Out Of Centralized Exchanges – Time To Buy?COIN:QNTUSDQuant
01/06/202407:00Business WireMassive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
01/06/202407:00GlobeNewswire Inc.Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024NASDAQ:MOLNMolecular Partners AG
01/06/202407:00GlobeNewswire Inc.CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes